Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N06AX34
|
| gptkbp:brand |
gptkb:Zurzuvae
|
| gptkbp:CASNumber |
2250289-00-3
|
| gptkbp:chemicalFormula |
C21H31NO2
|
| gptkbp:developer |
gptkb:Biogen
gptkb:Sage_Therapeutics |
| gptkbp:drugClass |
neuroactive steroid
|
| https://www.w3.org/2000/01/rdf-schema#label |
zuranolone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
positive allosteric modulator of GABA-A receptors
|
| gptkbp:molecularWeight |
329.48 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
dizziness fatigue urinary tract infection drowsiness |
| gptkbp:synonym |
gptkb:SAGE-217
|
| gptkbp:usedFor |
gptkb:major_depressive_disorder
postpartum depression |
| gptkbp:bfsParent |
gptkb:Zurzuvae
|
| gptkbp:bfsLayer |
6
|